Aviron
Pioneering advancements in antiviral therapy for chronic Hepatitis C Virus (HCV) infection through robust R&D and strategic collaborations.
Pioneering advancements in antiviral therapy for chronic Hepatitis C Virus (HCV) infection through robust R&D and strategic collaborations.
Aviron is a Health Care startup that was founded in 2001 with the slogan "Pioneering advancements in antiviral therapy for chronic Hepatitis C Virus (HCV) infection through robust R&D and strategic collaborations." The company focuses on the innovation and development of antiviral treatments specifically targeting chronic Hepatitis C Virus (HCV) infections. Aviron collaborates closely with organizations such as CHEMRAR Hi-Tech Center, Chemical Diversity Research Institute, and DRUGS TECHNOLOGY, Ltd.
The last investment in Aviron was a $18.50M Series A investment that took place on 27 February 2022. The investors in this round were Global Founders Capital, Formic Ventures, Stripes, and Mark Mastrov. Based in Moscow, Russian Federation, Aviron Ltd continues to drive its antiviral therapy research and development forward through strategic partnerships and robust R&D efforts.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $18.50M | 4 |
|
27 Feb 2022 |
| Seed Round | Unknown | 1 |
|
05 Jan 2012 |
No recent news or press coverage available for Aviron.
We care about your data, and we'd love to use cookies make your experience better.
